TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.
Tryptamine Therapeutics Limited has issued an addendum to its 2025 Annual General Meeting notice to include a new resolution for the appointment of BDO Audit Pty Ltd as the company’s auditor. This resolution, initially mentioned in a January announcement, was omitted from the original notice. The AGM will proceed as scheduled without changes to its date, time, or venue. This update ensures compliance and transparency in the company’s governance, potentially impacting stakeholder confidence positively.
More about Tryptamine Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing novel formulations of psilocin for use in psychotherapy to treat diseases with unmet medical needs. The company’s lead program, TRP-8803, aims to improve the administration of psilocin, potentially enhancing its efficacy and safety. Tryp has completed Phase 2a clinical trials for binge eating disorder and fibromyalgia and is conducting trials for irritable bowel syndrome.
Average Trading Volume: 2,095,577
Technical Sentiment Signal: Buy
Current Market Cap: A$54.72M
For an in-depth examination of TYP stock, go to TipRanks’ Overview page.